High-Precision Liver Ablation Using Stereotactic Guidance, CT Hepatic Arteriography, and Software Assessment for Tumor Treatment

What this Trial Is About

Researchers are investigating a high-precision liver ablation technique for patients with primary and secondary liver cancers, specifically colorectal liver metastasis. This technique combines stereotactic guidance, CT imaging during hepatic arteriography, and computer-based software to assess ablation margins. The study aims to evaluate the technical effectiveness and local tumor progression-free survival of this combined method, addressing the need for accurate tumor boundary definition, probe placement, and margin assessment during ablation procedures. The treatment involves a one-day percutaneous liver ablation procedure where an image-guidance device is used for planning and precise placement of the ablation needle within the tumor. This combined approach integrates multiple steps previously used separately, aiming to improve ablation accuracy. The study will focus on various outcomes including minimal ablation margins, adverse events, liver function, tissue properties, radiation exposure, and overall oncological results. Participants will undergo assessments including quality of life evaluations using the EQ-5D-3L questionnaire throughout the study, averaging about one year. Researchers will monitor tumor response, adverse events, and other clinical measures to understand the treatments impact. Safety and procedural times are also evaluated. The total participation duration covers the treatment day and follow-up assessments to track clinical outcomes and quality of life.

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)